{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:10:33Z","timestamp":1760004633778,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jpba.2023.115395","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:38:42Z","timestamp":1681447122000},"page":"115395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Establishment of certified reference material for the potency assay in yellow fever vaccine quality control, in accordance with International Standards Organization guidance"],"prefix":"10.1016","volume":"230","author":[{"given":"Ana Carolina Ferreira Ballest\u00ea","family":"Ajorio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius Pessanha","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anderson Peclat","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa Alvaro","family":"Diniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greice Maria Silva da","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen James","family":"Forsythe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor Barbosa","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Luiz Lima","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115395_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3390\/vaccines10030372","article-title":"Yellow fever: origin, epidemiology, preventive strategies and future prospects","volume":"10","author":"Gianchecchi","year":"2022","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.jpba.2023.115395_bib2","article-title":"Factors associated with severity of adverse events following yellow fever vaccination during the biggest outbreak of the disease recorded in Brazil, 2016-2017","volume":"29","author":"Lucena","year":"2020","journal-title":"Epidemiol. Serv. Saude"},{"key":"10.1016\/j.jpba.2023.115395_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40794-020-0101-0","article-title":"Yellow fever control: current epidemiology and vaccination strategies","volume":"6","author":"Chen","year":"2020","journal-title":"Trop. Dis. Travel. Med. Vaccin."},{"key":"10.1016\/j.jpba.2023.115395_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.biologicals.2005.09.005","article-title":"Molecular and phenotypic analysis of a working seed lot of yellow fever virus 17DD vaccine strain produced from the secondary seed lot 102\/84 with an additional passage in chicken embryos","volume":"34","author":"Marchevsky","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.jpba.2023.115395_bib5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/14760584.4.4.553","article-title":"Yellow fever vaccine","volume":"4","author":"Monath","year":"2005","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.jpba.2023.115395_bib6","unstructured":"Funda\u00e7\u00e3o Oswaldo Cruz. Relat\u00f3rio de gest\u00e3o do exerc\u00edcio de 2019. Coordena\u00e7\u00e3o-Geral de Planejamento Estrat\u00e9gico \u2013 Cogeplan\/Fiocruz Rio de Janeiro \u2013 RJ,2019, 138 p. https:\/\/portal.fiocruz.br\/sites\/portal.fiocruz.br\/files\/documentos\/20200826_rg2019_atualizado_com_correcoes_finais.pdf (accessed 8 February 2023)."},{"key":"10.1016\/j.jpba.2023.115395_bib7","unstructured":"World Health Organization (WHO). WHO good manufacturing practices for biological products. In: WHO Team: Health Product Policy and Standards, Technical Standards and Specifications. WHO Technical Report Series, No. 999, Annex 2, 2016. Geneva. World Health Organization, 2016."},{"key":"10.1016\/j.jpba.2023.115395_bib8","unstructured":"World Health Organization (WHO). Meeting Report. WHO Informal Consultation of the Minimum Potency Specification for Yellow Fever Vaccines National Institute for Biological Standards and Control (NIBSC). Potters Bar, UK, 2007."},{"key":"10.1016\/j.jpba.2023.115395_bib9","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Farmacopeia Brasileira. 6\u00aa edi\u00e7\u00e3o - produtos biol\u00f3gicos. Di\u00e1rio Oficial da Rep\u00fablica Federativa do Brasil. Bras\u00edlia, 12 de agosto de 2019."},{"key":"10.1016\/j.jpba.2023.115395_bib10","unstructured":"International Standards Organization. ISO Guide 30:2017. Reference materials - Selected terms and definitions. 3th Edition, 8 p. Geneva: ISO; 2015."},{"key":"10.1016\/j.jpba.2023.115395_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biologicals.2004.09.003","article-title":"Collaborative study to assess the suitability of a candidate International Standard for yellow fever vaccine","volume":"32","author":"Ferguson","year":"2004","journal-title":"Biologicals"},{"key":"10.1016\/j.jpba.2023.115395_bib12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1351\/pac200678010145","article-title":"The international harmonized protocol for the proficiency testing of analytical chemistry laboratories","volume":"78","author":"Thompson","year":"2006","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.jpba.2023.115395_bib13","first-page":"59","article-title":"Production of proficiency test items containing bacteria in chicken matrix using freeze-drying technique","volume":"9","author":"da Silva","year":"2021","journal-title":"Rev. Visa em Debate"},{"key":"10.1016\/j.jpba.2023.115395_bib14","unstructured":"International Standards Organization. ISO Guide 35:2017. Reference materials -Guidance for characterization and assessment of homogeneity and stability. 4th Edition, 105p. Geneva: ISO; 2017."},{"key":"10.1016\/j.jpba.2023.115395_bib15","article-title":"Manual for the establishment of the national and other secondary standard for vaccines. WHO\/IVB\/11.03","author":"World Health Organization (WHO)","year":"2011","journal-title":"Geneva"},{"key":"10.1016\/j.jpba.2023.115395_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.22239\/2317-269x.01259","article-title":"Alternative potency tests for quality control of immunobiologicals: a critical review of the validation approach","volume":"8","author":"Moreira","year":"2020","journal-title":"Rev. Visa em Debate"},{"key":"10.1016\/j.jpba.2023.115395_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.biologicals.2019.06.007","article-title":"Utility of reference materials for Zika Virus nucleic acid testing","volume":"61","author":"Kempster","year":"2019","journal-title":"Biologicals"},{"key":"10.1016\/j.jpba.2023.115395_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1286-4579(00)00288-4","article-title":"Stability-related studies on 17D yellow fever vaccine","volume":"2","author":"Perraut","year":"2000","journal-title":"Microbes Infect."},{"key":"10.1016\/j.jpba.2023.115395_bib19","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/03639045.2017.1412459","article-title":"Applying the methodology of design of experiments to stability studies: a partial least squares approach for evaluation of drug stability","volume":"44","author":"Jordan","year":"2018","journal-title":"Drug. Dev. Ind. Pharm."},{"key":"10.1016\/j.jpba.2023.115395_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41434-019-0072-9","article-title":"Stability of the adeno-associated virus 8 reference standard material","volume":"26","author":"Penaud-Budloo","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.jpba.2023.115395_bib21","doi-asserted-by":"crossref","DOI":"10.1590\/1981-6723.20817","article-title":"Microbiological reference material (bacterial and fungal domains): definition, production rules, use and need for establishment in Brazil","volume":"22","author":"Rosas","year":"2019","journal-title":"Braz. J. Food Technol."},{"key":"10.1016\/j.jpba.2023.115395_bib22","first-page":"47","article-title":"A WHO collaborative study of in vitro and in vivo methods for the assay of yellow fever vaccines","volume":"11","author":"Seagroatt","year":"1983"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523001644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523001644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:29:07Z","timestamp":1760002147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523001644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":22,"alternative-id":["S0731708523001644"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115395","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishment of certified reference material for the potency assay in yellow fever vaccine quality control, in accordance with International Standards Organization guidance","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115395"}}